Deponit BE/BA Submissions Supported By FDA Guidances - Schwarz Pharma
Executive Summary
Recent FDA guidances on bioequivalence support Schwarz Pharma's argument that it has submitted adequate BE and bioavailability data for its transdermal nitroglycerin product Deponit under the Drug Efficacy Study Implementation program, Schwarz argued in recent correspondence to FDA.